The plan is to issue CLs for Trastuzumab (or Herceptin, used for treating breast cancer), Ixabepilone (used for chemotherapy in breast cancer treatment) and Dasatinib (or Sprycel, for leukaemia).
Lobby group tells USTR it has got assurance from India on compulsory licensing.
Indian firm to soon launch copycat of anti-breast-cancer drug.
